Emerging therapies for cardiorenal protection in kidney transplant recipients, including SGLT2 inhibitors, finerenone, and semaglutide, represent promising strategies to mitigate the high cardiovascular and renal risks in this population. Here, SLC5A2 is linked to medical procedure.